Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
WATERTOWN, Mass., May 30, 2017 -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7, 2017 at 08:00 a.m. Eastern Time at the Grand Hyatt Hotel in New York City.
A live audio webcast of the Jefferies presentation will be available on the company’s website at http://ir.tphase.com/events.cfm. An archived presentation will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.
Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 [email protected] Argot Partners Maeve Conneighton 206-899-4940 [email protected] Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 [email protected]
